Observationa Study is a Prospective and Multi-institutional Observational Study.

Observational Study to Evaluate Effectiveness, Safety and Satisfaction Level of Zastaprazan (JAQBO®) Under Daily Treatment for Patients With Erosive Gastroesophageal Reflux Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06952855

Enrollment

5536

Registered

2025-05-01

Start date

2024-11-01

Completion date

2025-04-23

Last updated

2025-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acid Regurgitation, Erosive Reflux Disease, Heartburn

Keywords

GERD, ERD

Brief summary

This observational study is a prospective, multi-institutional non intervention study to examine the prescription patterns, corresponding treatment effects and safety in routine clinical practice for patients prescribed for the treatment of gastroesophageal reflux disease.

Detailed description

The present observational study is designed to check effect and safety for patients who have been prescribed JAQBO for the treatment of erosive gastroesophageal reflux disease.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

1. An adult over 19 years of age 2. A person who voluntarily provides written informed consent

Exclusion criteria

1. A pregnant woman or a nursing woman 2. A person who is deemed unsuitable for the subject of the study

Design outcomes

Primary

Measure	Time frame	Description
Change in GERD (heartburn, acid regurgitation) score in RDQ	4 weeks	Scale(none / 1day / 2day/ 3-4 day / 5-6 day/ every day)

Countries

South Korea

Outcome results